Secondary analysis of 645 postmenopausal, node-negative, hormone-positive early breast cancer patients from the TEAM pathology substudy: PREDICT 2.1, PREDICT v3 and RSClin showed moderate discrimination (C 0.66-0.70) but disagreed widely on chemotherapy benefit.
Secondary analysisn = 645 patients
Leblanc et al. Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy